EDAP Announces New Ablatherm HIFU Site at Cleveland Clinic Canada in Toronto, Canada
29 June 2010 - 10:30PM
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, announced today that Maple Leaf HIFU, the exclusive
distributor of Ablatherm HIFU in Canada, is installing an Ablatherm
device at their new medical office located at Cleveland Clinic
Canada in Toronto. Patients with localized prostate cancer are now
able to benefit from this minimally invasive HIFU procedure.
Marc Oczachowski, EDAP's Chief Executive Officer, commented, "I
am very pleased that Ablatherm HIFU technology is now available at
this location. This move supports our commitment to offer the
Ablatherm HIFU solution to a greater number of patients in North
America."
Dr. William Orovan, Maple Leaf HIFU's President and Medical
Director, added, "Since inception, our mission has been to provide
patients throughout North America with access to the latest proven
treatment option available for localized prostate cancer:
Ablatherm® High Intensity Focused Ultrasound. Our clinic
strives to be at the forefront of new and effective treatment
technology with the potential to provide greater efficacy, fewer
side effects, and better quality of life for patients and their
families."
Dr. Orovan continued, "Maple Leaf HIFU is proud to be operating
within the Canadian office of Cleveland Clinic. We have always
focused on providing the best possible care for our patients, and
we believe that our new location will assist us in achieving this
goal."
Prostate cancer patients interested in being treated by Maple
Leaf HIFU are advised to contact them at (877) 370-4438 or by
visiting www.hifu.ca.
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm, the most advanced
and clinically proven choice for high-intensity focused ultrasound
(HIFU) treatment of localized prostate cancer. HIFU treatment is
shown to be a minimally invasive and effective treatment option
with a low occurrence of side effects. Ablatherm-HIFU is generally
recommended for patients with localized prostate cancer (stages
T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy
treatment. Approved in Europe as a treatment for prostate cancer,
Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently
undergoing evaluation in a multicenter U.S. Phase II/III clinical
trial under an Investigational Device Exemption granted by the FDA,
the ENLIGHT U.S. clinical study. The Company also is developing
this technology for the potential treatment of certain other types
of tumors. EDAP TMS SA also produces and commercializes medical
equipment for treatment of urinary tract stones using
extra-corporeal shockwave lithotripsy (ESWL). For more information
on the Company, please visit http://www.edap-tms.com,
http://www.hifu-planet.com.
About Maple Leaf HIFU
Maple Leaf HIFU provides patients throughout North America with
access to the latest proven treatment option available for
localized prostate cancer: Ablatherm® High Intensity Focused
Ultrasound. Maple Leaf HIFU first started treating patients in
Toronto in 2005. Since that time more than 500 patients have
been treated at the clinic using Ablatherm HIFU, the most advanced
and clinically proven choice for high-intensity focused ultrasound
(HIFU) treatment of localized prostate cancer.
CONTACT: EDAP TMS SA
Investor Relations / Legal Affairs
Blandine Confort
+33 4 72 15 31 72
bconfort@edap-tms.com
The Ruth Group
Investors:
Stephanie Carrington
646-536-7017
scarrington@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024